GKGrzegorz Kowalski

Grzegorz Kowalski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Grzegorz Kowalski has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Beyond Cancer: Differences in Psychosocial Burden Between Patients with Chronic Non-Cancer Diagnoses Assessed Using the Integrated Palliative Outcome Scale

    by Monika Grochowicka, Monika Pyszczorska, Grzegorz Kowalski, Małgorzata Reysner, Tomasz Reysner, Wojciech Leppert, Katarzyna Wieczorowska-Tobis

    Background/Objectives: The Integrated Palliative Outcome Scale (IPOS) was developed for use in patients with advanced, life-limiting conditions. This study aimed to apply the IPOS in an inpatient hospice setting in Poland, incorporating both patient- and healthcare staff-reported perspectives in cancer and non-cancer populations. Methods: Patients’ needs were assessed in 112 individuals (86 patients with cancer [C] and 26 with non-cancer diagnoses [nC]) using the Polish version of the IPOS. Assessments were conducted twice: within 24 h of admission (A1) and after 7 days (A2). Results: The mean age of the study population was 73.9 ± 11.9 years, and 63 patients (56.2%) were male. At A1, the total IPOS score reported by staff was significantly lower than that reported by patients (p < 0.01), primarily due to lower scores in the psychosocial domain (p < 0.001), while somatic domain scores were comparable. At A2, no significant changes were observed in total IPOS scores or in any domain in either patient- or staff-reported assessments. At A1, total IPOS scores did not differ significantly between C and nC groups. However, psychosocial domain scores were higher in the nC group (p < 0.01). Patients with non-cancer conditions reported higher levels of anxiety (p < 0.05), as well as greater needs related to feeling at peace (p < 0.01), sharing feelings (p < 0.05), and access to information (p < 0.05). Conclusions: Our findings underscore the multidimensional nature of suffering and highlight the need for more comprehensive recognition and assessment of psychosocial needs in palliative care patients, particularly those with non-cancer diagnoses.

  • Low-Dose Perineural Dexamethasone Enhances Analgesia After Pediatric Hand Surgery Without Elevating Systemic Stress Markers: A Randomized Controlled Trial

    by Tomasz Reysner, Bahadir Ciftci, Szymon Bialka, Wojciech Gola, Piotr Czarecki, Pawel Pietraszek, Grzegorz Kowalski, Przemyslaw Daroszewski, Malgorzata Reysner

    Background: Supraclavicular brachial plexus block is a widely used technique for upper limb surgery in children. Although perineural dexamethasone has demonstrated efficacy in prolonging analgesia in adults, data on its optimal dosing and systemic safety in pediatric patients are limited. This study aimed to evaluate whether low-dose perineural dexamethasone can prolong postoperative analgesia without increasing systemic stress markers in young children undergoing hand or wrist surgery. Methods: In this triple-blinded, randomized controlled trial (ClinicalTrials.gov Identifier: NCT06086392), 90 children aged 3 months to 6 years undergoing elective upper extremity surgery were assigned to receive supraclavicular brachial plexus block with 0.2% ropivacaine combined with either normal saline (control), dexamethasone 0.05 mg/kg, or dexamethasone 0.1 mg/kg. The primary outcome was time from arrival in the postanesthesia care unit to first administration of rescue opioid analgesia. Secondary outcomes included total opioid consumption, postoperative pain intensity using the FLACC scale, blood glucose levels, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and time to motor recovery. Results: Both dexamethasone groups demonstrated significantly prolonged time to first opioid use compared with the control group (mean±SD: 19.4±2.2 h in the 0.1 mg/kg group, 16.0±1.9 h in the 0.05 mg/kg group, and 8.5±1.3 h in controls; P <0.0001). Total opioid consumption was significantly reduced in the dexamethasone groups. Postoperative pain scores were lower in both intervention groups, especially during the first 12 hours. No significant differences were found among groups in blood glucose, inflammatory markers, or incidence of nerve deficits. Motor recovery was delayed in the dexamethasone groups but did not interfere with early mobilization. Conclusions: Low-dose perineural dexamethasone (0.05 to 0.1 mg/kg) safely and effectively prolongs postoperative analgesia and reduces opioid needs in children undergoing upper limb surgery, without causing systemic metabolic or inflammatory disturbances. The 0.05 mg/kg dose may offer a more favorable balance between analgesic efficacy and motor recovery time. Level of Evidence: Level I—randomized controlled trial.


  • Open Access

    Erector spinae plane block in pediatric surgery: a systematic review and meta-analysis

    by Małgorzata Reysner, Tomasz Reysner, Grzegorz Kowalski, Piotr Janusz, Aleksander Mularski, Przemysław Daroszewski, Jerzy Kolasiński, Katarzyna Wieczorowska-Tobis

    The Erector Spinae Plane Block (ESPB) is a well-known regional anesthesia technique in adults. However, its effectiveness and analgesic efficiency have yet


  • Open Access

    Optimizing Postoperative Analgesia in Total Knee Arthroplasty

    by Tomasz Reysner, Grzegorz Kowalski, Aleksander Mularski, Anna Perek, Przemysław Daroszewski, Malgorzata Reysner

    Objectives: To assess the effect of perineural dexamethasone on analgesia duration and opioid consumption when used as an adjuvant to the iPACK (infiltration between the popliteal artery and capsule of the knee) block and adductor canal block in patients undergoing total knee arthroplasty. Methods: In this double-blind, randomized controlled trial, 60 patients aged 65 years or older undergoing total knee arthroplasty under spinal anesthesia were assigned to one of 2 groups. The control group received iPACK and adductor canal block with 0.2% ropivacaine alone, while the Dexamethasone group received the same blocks with the addition of perineural dexamethasone. The primary outcome was time to first opioid rescue analgesia. Secondary outcomes included total opioid consumption over 48 hours, postoperative pain scores at defined time points, quadriceps muscle strength, and adverse effects, including neurological complications and hyperglycemia. Results: Patients receiving dexamethasone experienced a significantly longer duration of analgesia (15.9±1.2 h vs. 8.8±1.6 h), lower total opioid consumption over 48 hours (1.2±1.3 mg vs. 2.3±1.4 mg morphine equivalents), and fewer patients required opioids (20% vs. 50%). Pain scores were significantly lower at 8 and 12 hours postoperatively. No differences were observed in motor function or adverse event rates. Discussion: Perineural dexamethasone enhanced the duration and quality of postoperative analgesia without compromising motor function. Its inclusion in regional analgesia protocols for total knee arthroplasty may contribute to improved recovery and reduced opioid use.


  • Open Access

    Reduced Ropivacaine Volume with Perineural Dexamethasone in PENG Block for Total Hip Arthroplasty: A Randomized Controlled Trial

    by Tomasz Reysner, Agnieszka Neumann-Podczaska, Pawel Pietraszek, Aleksander Mularski, Grzegorz Kowalski, Przemyslaw Daroszewski, Malgorzata Reysner

    Background/Objectives: The pericapsular nerve group (PENG) block is increasingly used as part of multimodal analgesia for total hip arthroplasty (THA). However, standard high-volume local anesthetic regimens may impair motor function. The addition of perineural dexamethasone could allow for volume reduction while maintaining analgesic efficacy and minimizing quadriceps weakness. This study evaluated whether adding dexamethasone to a low-volume PENG block prolongs analgesia, reduces opioid consumption, maintains pain control, and preserves motor function compared to a standard-volume PENG block. Materials and Methods: In this randomized controlled trial (NCT06470334), 60 adult patients undergoing THA via the direct superior approach received either a standard-volume PENG block with 20 mL of 0.2% ropivacaine (PENG group) or a low-volume block with 10 mL of 0.2% ropivacaine plus 4 mg of perineural dexamethasone (PENG + DEX group). The primary outcome was time to first rescue opioid. Secondary outcomes included total 48-h opioid consumption (oral morphine equivalents), pain scores (numeric rating scale, NRS) at rest and during movement, and quadriceps muscle strength at predefined postoperative intervals. Results: The PENG + DEX group demonstrated a significantly longer time to first opioid administration (15.0 ± 1.5 h vs. 9.1 ± 1.7 h; p < 0.0001) and reduced total opioid consumption within 48 h (2.3 ± 3.1 mEQ vs. 5.0 ± 4.4 mEQ; p = 0.0120). Pain scores were similar at 4 h but significantly lower in the PENG + DEX group at 8, 12, and 24 h postoperatively (all p < 0.01). Quadriceps strength was fully preserved in both groups at all assessed timepoints (p > 0.9999). Conclusions: The addition of perineural dexamethasone to a low-volume PENG block provides longer-lasting analgesia and reduces opioid requirements without compromising pain control or quadriceps function. This approach may improve the safety and efficacy of regional anesthesia in THA.


  • Open Access

    Symptom Burden and Quality of Life in Inpatient Palliative Care

    by Monika Grochowicka, Wojciech Leppert, Małgorzata Reysner, Sylwia Kropińska, Maciej Sopata, Tomasz Reysner, Grzegorz Kowalski, Katarzyna Wieczorowska–Tobis

    Effective palliative care requires a comprehensive assessment of symptoms to improve quality of life. This study evaluated the clinical utility of the Polish version of the Integrated Palliative Care Outcome Scale (IPOS-POL) in an inpatient setting. One hundred patients (68 oncological, 32 non-oncological) completed IPOS-POL at admission (T1) and after seven days (T2) between July 2022 and February 2023. While total IPOS scores remained stable (p = 0.3603), psychosocial distress increased significantly (p = 0.0217). Staff tended to underestimate drowsiness and psychosocial distress compared with patient self-reports. Female patients reported higher distress (p = 0.0374), and bedridden patients experienced more pain (p = 0.0146). Oncological patients reported greater pain (p = 0.0189), whereas non-oncological patients more frequently experienced breathlessness (p = 0.0297). These findings emphasize discrepancies in symptom perception between patients and staff and underline the importance of tailored interventions based on gender and functional status. Enhanced psychosocial support should be a priority in inpatient palliative care.


  • Open Access

    iPACK block with adductor canal block vs. lumbar erector spinae plane block (L-ESPB) in total knee arthroplasty: a randomized, double-blinded, controlled trial

    by Tomasz Reysner, Katarzyna Wieczorowska-Tobis, Grzegorz Kowalski, Lukasz Lapaj, Przemyslaw Daroszewski, Małgorzata Reysner

    Introduction: Total knee arthroplasty (TKA) is associated with severe pain. We examined whether an ultrasound-guided, single-injection L2 erector spinae plane block could improve analgesia compared to an ultrasound-guided iPACK (infiltration between the popliteal artery and capsule of the knee) block with adductor canal block (ACB) in patients undergoing TKA under spinal anesthesia.Material and methods: Ninety patients aged 65–89 years of both sexes (ASA I–III) scheduled for TKA were randomly allocated to receive iPACK block (ropivacaine 0.2%, 20 mL) with ACB (ropivacaine 0.2%, 10 mL), lumbar erector spinae plane block (L-ESPB) (ropivacaine 0.2%, 20 mL on each side), or to the control group. The primary outcome was total opioid consumption. The secondary outcomes included pain scores, time to first rescue opioid analgesia, quadriceps muscle strength, neutrophil-to-lymphocyte ratio (NLR), and platelet- to-lymphocyte ratio (PLR).Results: The total opioid consumption in 48 h was significantly lower in the iPACK+ACB group (mean ± SD) (3.0 ± 3.3) compared to L-ESPB (6.8 ± 3.8, P = 0.0442) and the control group (18.2 ± 4.0, P < 0.001). The time to first rescue opioid analgesia was longer in the iPACK+ACB (12.0 ± 1.9) compared to the L-ESPB (9.2 ± 1.9, P < 0.001) group and the control group (4.3 ± 1.1, P < 0.001). The pain scores, NLR, and PLR levels were significantly lower in the iPACK+ACB and L-ESPB groups than at all time points in the control group.Conclusions: The iPACK+ACB is more effective than L-ESPB in pain management following TKA. iPACK+ACB and the L-ESPB lowered total opioid consumption and prolonged time to first opioid analgesia. NLR and PLR levels did not differ between the groups.


  • Open Access

    Perineural dexamethasone enhances analgesic duration of erector spinae plane block in total hip arthroplasty: A randomized quadruple-blind controlled trial

    by Tomasz Reysner, Paweł Pietraszek, Tomasz Purat, Grzegorz Kowalski, Aleksander Mularski, Przemyslaw Daroszewski, Malgorzata Reysner


  • Open Access

    Effect of ultrasound-guided genicular nerve neurolysis versus sham procedure on pain in patients with knee osteoarthritis: a randomized clinical trial

    by Malgorzata Reysner, Tomasz Reysner, Grzegorz Kowalski, Aleksander Mularski, Przemyslaw Daroszewski, Katarzyna Wieczorowska-Tobis

    Importance: Knee osteoarthritis (OA) is a prevalent and disabling condition, especially in older adults. For patients who are not candidates for total knee arthroplasty (TKA) due to comorbidities or limited access to care, minimally invasive pain-relief options are critically needed. Objective: To assess the efficacy and safety of ultrasound-guided chemical neurolysis using 95% ethanol targeting four genicular nerves in patients with symptomatic knee OA who have not responded to conservative management. Design: Double-blind, randomized, sham-controlled clinical trial. Participants: A total of 100 adults with symptomatic knee OA, confirmed radiographically and unresponsive to conservative treatment, were enrolled and randomized. Interventions: Patients were randomized to receive ultrasound-guided chemical neurolysis of the superomedial, superolateral, recurrent tibial, and inferomedial genicular nerves with 95% ethanol (treatment group) or a sham procedure (control group). Main Outcomes and Measures: The primary outcome was pain intensity measured by the Numerical Rating Scale (NRS) at 7 days, 30 days, 3 months, and 6 months post-procedure. Secondary outcomes included opioid consumption and health-related quality of life measured by the EQ-5D-5L questionnaire. Safety outcomes focused on the occurrence of neurological complications. Analyses were conducted using an intention-to-treat approach with appropriate handling of missing data. Results: Patients in the ethanol neurolysis group experienced significantly greater reductions in NRS scores at all follow-up points compared to the sham group (P < .0001). Opioid consumption was also significantly reduced in the neurolysis group throughout the 6-month period (P < .0001). Quality of life, as assessed by EQ-5D-5L, improved significantly in the treatment group (P < .0001). No neurological deficits or serious adverse events were reported in either group. Conclusions and Relevance: Ultrasound-guided chemical neurolysis of the SMGN, SLGN, RTGN, and IMGN with 95% ethanol is a safe and effective minimally invasive treatment for patients with refractory knee OA pain. It significantly reduces pain and opioid use while improving quality of life, making it a valuable therapeutic option for individuals ineligible for surgical intervention.